In 2014, MAPS spun out a separate division to immediate analysis and put together for an eventual FDA software, which it submitted at the conclusion of final 12 months. In early 2024, that offshoot was renamed Lykos Therapeutics.Pseudohallucinations: it does not bring about hallucinations per se but